Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

RON (recepteur d'origine nantais) and MET (hepatocyte growth factor receptor) are tyrosine kinase receptors. Various cancers have aberrant RON and MET expression and activation, which contribute to cancer cell proliferation, invasiveness, and metastasis. Here, we explored RON and MET expression...

Full description

Bibliographic Details
Main Authors: Chen-Yu Hu, Xiang-Ming Xu, Bo Hong, Zhi-Gang Wu, Yun Qian, Tian-Hao Weng, Yi-Zhi Liu, Tao-Ming Tang, Ming-Hai Wang, Hang-Ping Yao
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-12-01
Series:Frontiers in Oncology
Subjects:
pancreatic cancer
tyrosine kinase inhibitors
RON receptor tyrosine kinase
MET receptor tyrosine kinase
prognosis biomarker
therapeutic target
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01377/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01377/full

Similar Items